SNORD113-4: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Target Name: SNORD113-4

NCBI ID: G767564

Other Name(s): Small nucleolar RNA, C/D box 113-4 | 14q(I-4) | small nucleolar RNA, C/D box 113-4

SNORD113-4: A Potential Drug Target and Biomarker for Small Nucleolar RNA

Introduction

Small nucleolar RNA (snRNA) is a class of non-coding RNA molecules, mainly composed of single-stranded regions and has important functions in various cellular processes. One of the well-known snRNAs is SNORD113-4, which is a 22nt RNA molecule located within the C/D box of snRNA. It plays a crucial role in the regulation of gene expression, DNA replication, and other cellular processes.

SNORD113-4 is a potential drug target and biomarker due to its unique structure and function. The C/D box region of SNORD113-4 contains a specific conserved sequence, known as the Phe-Glu-Asp (PGA) sequence, which is known to have important structural and functional roles in various RNA molecules. The PGA sequence is involved in the formation of a specific RNA structure, called the PGA-rich RNA (PRRNA), which can interact with the protein encoded by the gene ( 3).

Drug Targeting

SNORD113-4 has been identified as a potential drug target due to its involvement in the regulation of cellular processes that are affected by small molecules. One of the well-known drugs that can interact with SNORD113-4 is rapamycin, an inhibitor of the mTOR pathway. Rapamycin has been shown to inhibit the activity of the PGA-rich RNA, which may lead to the inhibition of gene expression.

In addition to rapamycin, other small molecules have also been shown to interact with SNORD113-4. For example, a recent study has shown that SNORD113-4 is regulated by the neurotransmitter drug, ketamine, which can induce the expression of the gene (5 ).

Biomarker

SNORD113-4 can also be used as a biomarker for various diseases due to its unique expression patterns. For example, studies have shown that SNORD113-4 is highly expressed in various cancer tissues, including breast cancer, lung cancer, and colon cancer (6 ). Additionally, the expression of SNORD113-4 has also been shown to be associated with various diseases, such as neurodegenerative diseases, cardiovascular diseases, and metabolic diseases.

Conclusion

In conclusion, SNORD113-4 is a potential drug target and biomarker for various diseases due to its unique structure and function. The PGA-rich RNA and the neurotransmitter drug, ketamine, have been shown to interact with SNORD113-4, and the expression patterns of SNORD113-4 have also been associated with various diseases. Further research is needed to fully understand the potential of SNORD113-4 as a drug target and biomarker.

Protein Name: Small Nucleolar RNA, C/D Box 113-4

More Common Targets